MedTech Acquisition Corporation
MTACU
NASDAQ Capital Market11.35
USD
+1.30
- -
CIK
0001826667
ISIN
US58507N2045
CUSIP
58507N204
Return %
Stock
S&P500
1Y
16.05
18.21
3Y
9.56
64.38
5Y
9.56
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christopher C. Dewey
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 48 Maple Avenue Greenwich CT United States of America 06830
- IPO Date
- Dec 18, 2020
- CIK
- 0001826667
- Similar Companies
- Business
- MedTech Acquisition Corporation MedTech Acquisition Corporation (MTACU) operates as a special purpose acquisition company focused on mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations with one or more businesses in the medical technology and healthcare sectors, primarily in the United States; it targets innovative companies in areas such as diagnostic imaging, minimally invasive devices, regenerative medicine, digital health, oncology therapeutics, and drug delivery technologies including infusion systems like TriNav. Incorporated in 2020 and headquartered at 48 Maple Avenue in Greenwich, Connecticut, the company conducts operations across North America with consideration for opportunities in Europe and Asia, leveraging a management team with expertise in medical device development, regulatory affairs, healthcare investing, due diligence, and post-acquisition integration to identify targets with strong intellectual property, clinical data, and commercialization potential. In its most significant development, MedTech Acquisition Corporation completed a reverse merger with TriSalus Life Sciences, Inc. on August 10, 2023, following shareholder approval on August 8, 2023 and an announcement on November 14, 2022, resulting in the combined entity trading under new symbols (TLSI, TLSIW) while providing TriSalus with over $60 million in cash to advance its FDA-cleared TriNav Infusion System utilizing pressure-enabled drug delivery (PEDD) for liver and pancreatic tumors, investigational immunotherapeutics like SD-101, and related expansion initiatives; prior to this, a proposed merger with Memic Innovative Surgery Ltd. terminated due to market volatility.
MedTech Acquisition (OTCMKTS:MTACU) Shares Up 19.5% – What’s Next?
MedTech Acquisition (OTCMKTS:MTACU) Stock Price Up 19.5% – Here’s Why
Magnetar Financial LLC Reduces Stake in MedTech Acquisition Corp
MedTech Acquisition Corporation Announces Separate Trading of its Class A Common Stock and Warrants, Commencing February 8, 2021
MedTech Acquisition Corporation Announces Closing of Upsized $250,000,000 Initial Public Offering